nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—Optic atrophy—Lomustine—brain cancer	0.0268	0.103	CcSEcCtD
Lithium—IMPA2—Teniposide—Etoposide—brain cancer	0.0126	1	CbGdCrCtD
Lithium—IMPA1—telencephalon—brain cancer	0.0124	0.0524	CbGeAlD
Lithium—GRIA3—telencephalon—brain cancer	0.0106	0.0445	CbGeAlD
Lithium—IMPA1—gonad—brain cancer	0.0104	0.0437	CbGeAlD
Lithium—Papilloedema—Procarbazine—brain cancer	0.0103	0.0395	CcSEcCtD
Lithium—Blindness—Lomustine—brain cancer	0.00928	0.0357	CcSEcCtD
Lithium—GSK3B—telencephalon—brain cancer	0.00916	0.0386	CbGeAlD
Lithium—GRIA3—medulla oblongata—brain cancer	0.00832	0.035	CbGeAlD
Lithium—GSK3A—telencephalon—brain cancer	0.00797	0.0335	CbGeAlD
Lithium—IMPA1—endocrine gland—brain cancer	0.00785	0.033	CbGeAlD
Lithium—IMPA1—head—brain cancer	0.00775	0.0326	CbGeAlD
Lithium—GSK3B—gonad—brain cancer	0.00765	0.0322	CbGeAlD
Lithium—IMPA2—pituitary gland—brain cancer	0.00761	0.032	CbGeAlD
Lithium—GRIA3—midbrain—brain cancer	0.0076	0.032	CbGeAlD
Lithium—GRIA3—spinal cord—brain cancer	0.00742	0.0312	CbGeAlD
Lithium—Slurred speech—Procarbazine—brain cancer	0.0073	0.0281	CcSEcCtD
Lithium—GSK3B—medulla oblongata—brain cancer	0.0072	0.0303	CbGeAlD
Lithium—IMPA1—central nervous system—brain cancer	0.00707	0.0298	CbGeAlD
Lithium—GSK3A—gonad—brain cancer	0.00665	0.028	CbGeAlD
Lithium—GRIA3—head—brain cancer	0.00659	0.0277	CbGeAlD
Lithium—GSK3A—pituitary gland—brain cancer	0.00649	0.0273	CbGeAlD
Lithium—GSK3B—spinal cord—brain cancer	0.00642	0.027	CbGeAlD
Lithium—GSK3A—medulla oblongata—brain cancer	0.00626	0.0263	CbGeAlD
Lithium—GRIA3—central nervous system—brain cancer	0.00602	0.0253	CbGeAlD
Lithium—GRIA3—cerebellum—brain cancer	0.00588	0.0247	CbGeAlD
Lithium—GSK3B—endocrine gland—brain cancer	0.00578	0.0243	CbGeAlD
Lithium—GSK3A—midbrain—brain cancer	0.00572	0.0241	CbGeAlD
Lithium—GSK3B—head—brain cancer	0.00571	0.024	CbGeAlD
Lithium—IMPA1—brain—brain cancer	0.00562	0.0236	CbGeAlD
Lithium—GSK3A—spinal cord—brain cancer	0.00558	0.0235	CbGeAlD
Lithium—Dysarthria—Lomustine—brain cancer	0.00543	0.0209	CcSEcCtD
Lithium—Optic neuritis—Procarbazine—brain cancer	0.0053	0.0204	CcSEcCtD
Lithium—GSK3B—central nervous system—brain cancer	0.00521	0.0219	CbGeAlD
Lithium—GSK3B—cerebellum—brain cancer	0.00509	0.0214	CbGeAlD
Lithium—GSK3A—endocrine gland—brain cancer	0.00503	0.0211	CbGeAlD
Lithium—GSK3A—head—brain cancer	0.00496	0.0209	CbGeAlD
Lithium—Intracranial pressure increased—Carmustine—brain cancer	0.00489	0.0188	CcSEcCtD
Lithium—GRIA3—brain—brain cancer	0.00478	0.0201	CbGeAlD
Lithium—Nystagmus—Procarbazine—brain cancer	0.00457	0.0176	CcSEcCtD
Lithium—GSK3A—central nervous system—brain cancer	0.00453	0.0191	CbGeAlD
Lithium—GSK3A—cerebellum—brain cancer	0.00443	0.0186	CbGeAlD
Lithium—IMPA2—brain—brain cancer	0.00421	0.0177	CbGeAlD
Lithium—GSK3B—brain—brain cancer	0.00414	0.0174	CbGeAlD
Lithium—Lethargy—Lomustine—brain cancer	0.00381	0.0146	CcSEcCtD
Lithium—GSK3A—brain—brain cancer	0.0036	0.0151	CbGeAlD
Lithium—Ataxia—Lomustine—brain cancer	0.00351	0.0135	CcSEcCtD
Lithium—Dysarthria—Procarbazine—brain cancer	0.00345	0.0133	CcSEcCtD
Lithium—Skin ulcer—Hydroxyurea—brain cancer	0.00324	0.0125	CcSEcCtD
Lithium—Coma—Procarbazine—brain cancer	0.00298	0.0115	CcSEcCtD
Lithium—Stupor—Carmustine—brain cancer	0.00273	0.0105	CcSEcCtD
Lithium—Scotoma—Carmustine—brain cancer	0.00269	0.0103	CcSEcCtD
Lithium—Extrapyramidal disorder—Temozolomide—brain cancer	0.00262	0.0101	CcSEcCtD
Lithium—Scotoma—Temozolomide—brain cancer	0.0026	0.01	CcSEcCtD
Lithium—Optic neuritis—Etoposide—brain cancer	0.00257	0.00987	CcSEcCtD
Lithium—Memory impairment—Temozolomide—brain cancer	0.00251	0.00967	CcSEcCtD
Lithium—Lethargy—Procarbazine—brain cancer	0.00242	0.0093	CcSEcCtD
Lithium—Alopecia—Lomustine—brain cancer	0.00228	0.00877	CcSEcCtD
Lithium—Ataxia—Procarbazine—brain cancer	0.00223	0.00857	CcSEcCtD
Lithium—Leukocytosis—Carmustine—brain cancer	0.00217	0.00836	CcSEcCtD
Lithium—Coordination abnormal—Carmustine—brain cancer	0.00208	0.008	CcSEcCtD
Lithium—Coordination abnormal—Temozolomide—brain cancer	0.00201	0.00773	CcSEcCtD
Lithium—Depressed level of consciousness—Carmustine—brain cancer	0.00197	0.00758	CcSEcCtD
Lithium—Urinary incontinence—Carmustine—brain cancer	0.00197	0.00758	CcSEcCtD
Lithium—Depressed level of consciousness—Temozolomide—brain cancer	0.0019	0.00733	CcSEcCtD
Lithium—Urinary incontinence—Temozolomide—brain cancer	0.0019	0.00733	CcSEcCtD
Lithium—Coma—Carmustine—brain cancer	0.00187	0.00718	CcSEcCtD
Lithium—Drowsiness—Procarbazine—brain cancer	0.00183	0.00702	CcSEcCtD
Lithium—Chest discomfort—Etoposide—brain cancer	0.00178	0.00686	CcSEcCtD
Lithium—Anorexia—Lomustine—brain cancer	0.00175	0.00672	CcSEcCtD
Lithium—Swelling—Carmustine—brain cancer	0.00168	0.00646	CcSEcCtD
Lithium—Body temperature increased—Carboplatin—brain cancer	0.00166	0.00637	CcSEcCtD
Lithium—Hallucination—Procarbazine—brain cancer	0.00163	0.00627	CcSEcCtD
Lithium—Decreased appetite—Lomustine—brain cancer	0.00159	0.00613	CcSEcCtD
Lithium—Thirst—Temozolomide—brain cancer	0.0015	0.00579	CcSEcCtD
Lithium—Arrhythmia—Procarbazine—brain cancer	0.00146	0.00563	CcSEcCtD
Lithium—Body temperature increased—Lomustine—brain cancer	0.00145	0.00558	CcSEcCtD
Lithium—Alopecia—Procarbazine—brain cancer	0.00145	0.00557	CcSEcCtD
Lithium—Weight increased—Hydroxyurea—brain cancer	0.00144	0.00555	CcSEcCtD
Lithium—Drowsiness—Hydroxyurea—brain cancer	0.00141	0.00544	CcSEcCtD
Lithium—Ataxia—Carmustine—brain cancer	0.00139	0.00536	CcSEcCtD
Lithium—Ataxia—Temozolomide—brain cancer	0.00135	0.00518	CcSEcCtD
Lithium—Tremor—Procarbazine—brain cancer	0.00134	0.00514	CcSEcCtD
Lithium—Dehydration—Temozolomide—brain cancer	0.00133	0.00512	CcSEcCtD
Lithium—Dry skin—Temozolomide—brain cancer	0.00131	0.00505	CcSEcCtD
Lithium—Muscular weakness—Carmustine—brain cancer	0.00131	0.00503	CcSEcCtD
Lithium—Swelling—Etoposide—brain cancer	0.0013	0.005	CcSEcCtD
Lithium—Syncope—Procarbazine—brain cancer	0.00128	0.00492	CcSEcCtD
Lithium—Muscular weakness—Temozolomide—brain cancer	0.00126	0.00486	CcSEcCtD
Lithium—Hallucination—Hydroxyurea—brain cancer	0.00126	0.00485	CcSEcCtD
Lithium—Loss of consciousness—Procarbazine—brain cancer	0.00125	0.00482	CcSEcCtD
Lithium—Convulsion—Procarbazine—brain cancer	0.00124	0.00476	CcSEcCtD
Lithium—Arthralgia—Procarbazine—brain cancer	0.00121	0.00467	CcSEcCtD
Lithium—Dry mouth—Procarbazine—brain cancer	0.00119	0.00457	CcSEcCtD
Lithium—Confusional state—Procarbazine—brain cancer	0.00117	0.00452	CcSEcCtD
Lithium—Vomiting—Lomustine—brain cancer	0.00117	0.00449	CcSEcCtD
Lithium—Oedema—Procarbazine—brain cancer	0.00116	0.00448	CcSEcCtD
Lithium—Hyperglycaemia—Carmustine—brain cancer	0.00116	0.00445	CcSEcCtD
Lithium—Shock—Procarbazine—brain cancer	0.00115	0.00441	CcSEcCtD
Lithium—Erectile dysfunction—Temozolomide—brain cancer	0.00114	0.00439	CcSEcCtD
Lithium—Weight increased—Temozolomide—brain cancer	0.00113	0.00433	CcSEcCtD
Lithium—Alopecia—Hydroxyurea—brain cancer	0.00112	0.00431	CcSEcCtD
Lithium—Weight decreased—Temozolomide—brain cancer	0.00112	0.00431	CcSEcCtD
Lithium—Hyperglycaemia—Temozolomide—brain cancer	0.00112	0.0043	CcSEcCtD
Lithium—Anorexia—Procarbazine—brain cancer	0.00111	0.00427	CcSEcCtD
Lithium—Nausea—Lomustine—brain cancer	0.00109	0.00419	CcSEcCtD
Lithium—Hypotension—Procarbazine—brain cancer	0.00109	0.00419	CcSEcCtD
Lithium—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00106	0.00408	CcSEcCtD
Lithium—Somnolence—Procarbazine—brain cancer	0.00103	0.00398	CcSEcCtD
Lithium—Hallucination—Carmustine—brain cancer	0.00102	0.00392	CcSEcCtD
Lithium—Decreased appetite—Procarbazine—brain cancer	0.00101	0.00389	CcSEcCtD
Lithium—Fatigue—Procarbazine—brain cancer	0.001	0.00386	CcSEcCtD
Lithium—Hallucination—Temozolomide—brain cancer	0.000986	0.00379	CcSEcCtD
Lithium—Feeling abnormal—Procarbazine—brain cancer	0.000959	0.00369	CcSEcCtD
Lithium—Convulsion—Hydroxyurea—brain cancer	0.000956	0.00368	CcSEcCtD
Lithium—Gastrointestinal pain—Procarbazine—brain cancer	0.000952	0.00366	CcSEcCtD
Lithium—Discomfort—Hydroxyurea—brain cancer	0.000928	0.00357	CcSEcCtD
Lithium—Tinnitus—Temozolomide—brain cancer	0.000924	0.00355	CcSEcCtD
Lithium—Abdominal pain—Procarbazine—brain cancer	0.00092	0.00354	CcSEcCtD
Lithium—Body temperature increased—Procarbazine—brain cancer	0.00092	0.00354	CcSEcCtD
Lithium—Arrhythmia—Carmustine—brain cancer	0.000916	0.00352	CcSEcCtD
Lithium—Alopecia—Carmustine—brain cancer	0.000906	0.00349	CcSEcCtD
Lithium—Oedema—Hydroxyurea—brain cancer	0.000901	0.00347	CcSEcCtD
Lithium—Alopecia—Temozolomide—brain cancer	0.000875	0.00337	CcSEcCtD
Lithium—Anorexia—Hydroxyurea—brain cancer	0.000859	0.0033	CcSEcCtD
Lithium—Dysgeusia—Temozolomide—brain cancer	0.000844	0.00325	CcSEcCtD
Lithium—Vision blurred—Carmustine—brain cancer	0.000841	0.00324	CcSEcCtD
Lithium—Tremor—Carmustine—brain cancer	0.000836	0.00322	CcSEcCtD
Lithium—Asthenia—Procarbazine—brain cancer	0.000835	0.00321	CcSEcCtD
Lithium—Agitation—Carmustine—brain cancer	0.00082	0.00316	CcSEcCtD
Lithium—Vision blurred—Temozolomide—brain cancer	0.000813	0.00313	CcSEcCtD
Lithium—Tremor—Temozolomide—brain cancer	0.000808	0.00311	CcSEcCtD
Lithium—Somnolence—Hydroxyurea—brain cancer	0.000801	0.00308	CcSEcCtD
Lithium—Diarrhoea—Procarbazine—brain cancer	0.000796	0.00306	CcSEcCtD
Lithium—Dyspepsia—Hydroxyurea—brain cancer	0.000793	0.00305	CcSEcCtD
Lithium—Agitation—Temozolomide—brain cancer	0.000792	0.00305	CcSEcCtD
Lithium—Angioedema—Temozolomide—brain cancer	0.000788	0.00303	CcSEcCtD
Lithium—Decreased appetite—Hydroxyurea—brain cancer	0.000783	0.00301	CcSEcCtD
Lithium—Fatigue—Hydroxyurea—brain cancer	0.000777	0.00299	CcSEcCtD
Lithium—Vertigo—Temozolomide—brain cancer	0.000775	0.00298	CcSEcCtD
Lithium—Convulsion—Carmustine—brain cancer	0.000773	0.00297	CcSEcCtD
Lithium—Dizziness—Procarbazine—brain cancer	0.00077	0.00296	CcSEcCtD
Lithium—Convulsion—Temozolomide—brain cancer	0.000747	0.00287	CcSEcCtD
Lithium—Feeling abnormal—Hydroxyurea—brain cancer	0.000742	0.00286	CcSEcCtD
Lithium—Vomiting—Procarbazine—brain cancer	0.00074	0.00285	CcSEcCtD
Lithium—Confusional state—Carmustine—brain cancer	0.000734	0.00283	CcSEcCtD
Lithium—Arthralgia—Temozolomide—brain cancer	0.000734	0.00282	CcSEcCtD
Lithium—Rash—Procarbazine—brain cancer	0.000734	0.00282	CcSEcCtD
Lithium—Dermatitis—Procarbazine—brain cancer	0.000733	0.00282	CcSEcCtD
Lithium—Headache—Procarbazine—brain cancer	0.000729	0.00281	CcSEcCtD
Lithium—Oedema—Carmustine—brain cancer	0.000728	0.0028	CcSEcCtD
Lithium—Discomfort—Temozolomide—brain cancer	0.000725	0.00279	CcSEcCtD
Lithium—Dry mouth—Temozolomide—brain cancer	0.000718	0.00276	CcSEcCtD
Lithium—Body temperature increased—Hydroxyurea—brain cancer	0.000712	0.00274	CcSEcCtD
Lithium—Confusional state—Temozolomide—brain cancer	0.00071	0.00273	CcSEcCtD
Lithium—Oedema—Temozolomide—brain cancer	0.000704	0.00271	CcSEcCtD
Lithium—Alopecia—Etoposide—brain cancer	0.0007	0.0027	CcSEcCtD
Lithium—Anorexia—Carmustine—brain cancer	0.000694	0.00267	CcSEcCtD
Lithium—Nausea—Procarbazine—brain cancer	0.000691	0.00266	CcSEcCtD
Lithium—Hypotension—Carmustine—brain cancer	0.000681	0.00262	CcSEcCtD
Lithium—Dysgeusia—Etoposide—brain cancer	0.000676	0.0026	CcSEcCtD
Lithium—Anorexia—Temozolomide—brain cancer	0.000671	0.00258	CcSEcCtD
Lithium—Musculoskeletal discomfort—Carmustine—brain cancer	0.000664	0.00255	CcSEcCtD
Lithium—Somnolence—Carmustine—brain cancer	0.000647	0.00249	CcSEcCtD
Lithium—Asthenia—Hydroxyurea—brain cancer	0.000646	0.00249	CcSEcCtD
Lithium—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000641	0.00247	CcSEcCtD
Lithium—Decreased appetite—Carmustine—brain cancer	0.000633	0.00244	CcSEcCtD
Lithium—Somnolence—Temozolomide—brain cancer	0.000626	0.00241	CcSEcCtD
Lithium—Vertigo—Etoposide—brain cancer	0.00062	0.00239	CcSEcCtD
Lithium—Dyspepsia—Temozolomide—brain cancer	0.00062	0.00238	CcSEcCtD
Lithium—Diarrhoea—Hydroxyurea—brain cancer	0.000616	0.00237	CcSEcCtD
Lithium—Decreased appetite—Temozolomide—brain cancer	0.000612	0.00235	CcSEcCtD
Lithium—Fatigue—Temozolomide—brain cancer	0.000607	0.00233	CcSEcCtD
Lithium—Loss of consciousness—Etoposide—brain cancer	0.000606	0.00233	CcSEcCtD
Lithium—Feeling abnormal—Carmustine—brain cancer	0.0006	0.00231	CcSEcCtD
Lithium—Convulsion—Etoposide—brain cancer	0.000598	0.0023	CcSEcCtD
Lithium—Dizziness—Hydroxyurea—brain cancer	0.000596	0.00229	CcSEcCtD
Lithium—Gastrointestinal pain—Carmustine—brain cancer	0.000596	0.00229	CcSEcCtD
Lithium—Discomfort—Etoposide—brain cancer	0.00058	0.00223	CcSEcCtD
Lithium—Feeling abnormal—Temozolomide—brain cancer	0.00058	0.00223	CcSEcCtD
Lithium—Abdominal pain—Carmustine—brain cancer	0.000576	0.00222	CcSEcCtD
Lithium—Body temperature increased—Carmustine—brain cancer	0.000576	0.00222	CcSEcCtD
Lithium—Gastrointestinal pain—Temozolomide—brain cancer	0.000575	0.00221	CcSEcCtD
Lithium—Vomiting—Hydroxyurea—brain cancer	0.000573	0.0022	CcSEcCtD
Lithium—Rash—Hydroxyurea—brain cancer	0.000568	0.00219	CcSEcCtD
Lithium—Confusional state—Etoposide—brain cancer	0.000568	0.00218	CcSEcCtD
Lithium—Dermatitis—Hydroxyurea—brain cancer	0.000567	0.00218	CcSEcCtD
Lithium—Headache—Hydroxyurea—brain cancer	0.000564	0.00217	CcSEcCtD
Lithium—Abdominal pain—Temozolomide—brain cancer	0.000556	0.00214	CcSEcCtD
Lithium—Body temperature increased—Temozolomide—brain cancer	0.000556	0.00214	CcSEcCtD
Lithium—Anorexia—Etoposide—brain cancer	0.000537	0.00207	CcSEcCtD
Lithium—Nausea—Hydroxyurea—brain cancer	0.000535	0.00206	CcSEcCtD
Lithium—Hypotension—Etoposide—brain cancer	0.000526	0.00202	CcSEcCtD
Lithium—Asthenia—Carmustine—brain cancer	0.000523	0.00201	CcSEcCtD
Lithium—Asthenia—Temozolomide—brain cancer	0.000505	0.00194	CcSEcCtD
Lithium—Somnolence—Etoposide—brain cancer	0.000501	0.00193	CcSEcCtD
Lithium—Diarrhoea—Carmustine—brain cancer	0.000498	0.00192	CcSEcCtD
Lithium—Decreased appetite—Etoposide—brain cancer	0.00049	0.00188	CcSEcCtD
Lithium—Fatigue—Etoposide—brain cancer	0.000486	0.00187	CcSEcCtD
Lithium—Dizziness—Carmustine—brain cancer	0.000482	0.00185	CcSEcCtD
Lithium—Diarrhoea—Temozolomide—brain cancer	0.000482	0.00185	CcSEcCtD
Lithium—Dizziness—Temozolomide—brain cancer	0.000465	0.00179	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—brain cancer	0.000464	0.00179	CcSEcCtD
Lithium—Vomiting—Carmustine—brain cancer	0.000463	0.00178	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—brain cancer	0.000461	0.00177	CcSEcCtD
Lithium—Rash—Carmustine—brain cancer	0.000459	0.00177	CcSEcCtD
Lithium—Dermatitis—Carmustine—brain cancer	0.000459	0.00177	CcSEcCtD
Lithium—Headache—Carmustine—brain cancer	0.000456	0.00176	CcSEcCtD
Lithium—Vomiting—Temozolomide—brain cancer	0.000447	0.00172	CcSEcCtD
Lithium—Abdominal pain—Etoposide—brain cancer	0.000445	0.00171	CcSEcCtD
Lithium—Body temperature increased—Etoposide—brain cancer	0.000445	0.00171	CcSEcCtD
Lithium—Rash—Temozolomide—brain cancer	0.000444	0.00171	CcSEcCtD
Lithium—Dermatitis—Temozolomide—brain cancer	0.000443	0.00171	CcSEcCtD
Lithium—Headache—Temozolomide—brain cancer	0.000441	0.0017	CcSEcCtD
Lithium—Nausea—Carmustine—brain cancer	0.000433	0.00166	CcSEcCtD
Lithium—Nausea—Temozolomide—brain cancer	0.000418	0.00161	CcSEcCtD
Lithium—Asthenia—Etoposide—brain cancer	0.000404	0.00155	CcSEcCtD
Lithium—Diarrhoea—Etoposide—brain cancer	0.000385	0.00148	CcSEcCtD
Lithium—Dizziness—Etoposide—brain cancer	0.000372	0.00143	CcSEcCtD
Lithium—Vomiting—Etoposide—brain cancer	0.000358	0.00138	CcSEcCtD
Lithium—Rash—Etoposide—brain cancer	0.000355	0.00137	CcSEcCtD
Lithium—Dermatitis—Etoposide—brain cancer	0.000355	0.00137	CcSEcCtD
Lithium—Headache—Etoposide—brain cancer	0.000353	0.00136	CcSEcCtD
Lithium—Nausea—Etoposide—brain cancer	0.000335	0.00129	CcSEcCtD
Lithium—GSK3B—DAP12 signaling—ERBB2—brain cancer	0.000329	0.000671	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—EGFR—brain cancer	0.000328	0.000669	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—APC—brain cancer	0.000327	0.000667	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—RELA—brain cancer	0.000326	0.000666	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—brain cancer	0.000326	0.000665	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DTX2—brain cancer	0.000326	0.000665	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—brain cancer	0.000324	0.000662	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HES5—brain cancer	0.000323	0.00066	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—MYC—brain cancer	0.000323	0.00066	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—STAT3—brain cancer	0.000319	0.000652	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—CTNNB1—brain cancer	0.000319	0.000652	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—VAV1—brain cancer	0.000317	0.000647	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STRADA—brain cancer	0.000314	0.000641	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—EGFR—brain cancer	0.000313	0.000639	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—STAT3—brain cancer	0.000312	0.000638	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—EGFR—brain cancer	0.000312	0.000636	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—RELA—brain cancer	0.000311	0.000636	CbGpPWpGaD
Lithium—GSK3A—Disease—IDH1—brain cancer	0.000311	0.000634	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—EGFR—brain cancer	0.00031	0.000633	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—ERBB2—brain cancer	0.000309	0.000632	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—ERBB2—brain cancer	0.000309	0.000632	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—ERBB2—brain cancer	0.000309	0.000632	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—EGFR—brain cancer	0.000308	0.00063	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDK4—brain cancer	0.000307	0.000628	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IRS2—brain cancer	0.000307	0.000628	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SKP2—brain cancer	0.000307	0.000627	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—ERBB2—brain cancer	0.000307	0.000626	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—EGFR—brain cancer	0.000304	0.000621	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—ERBB2—brain cancer	0.000304	0.000621	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	0.000303	0.00062	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—APC—brain cancer	0.000303	0.000619	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—ERBB2—brain cancer	0.000303	0.000618	CbGpPWpGaD
Lithium—GSK3A—Disease—HEY1—brain cancer	0.000295	0.000601	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—ERBB2—brain cancer	0.000292	0.000597	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—EGFR—brain cancer	0.00029	0.000593	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—EGFR—brain cancer	0.00029	0.000593	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	0.00029	0.000593	CbGpPWpGaD
Lithium—GSK3A—Disease—DLL1—brain cancer	0.000289	0.00059	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—RELA—brain cancer	0.000288	0.000588	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—EGFR—brain cancer	0.000288	0.000587	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—RELA—brain cancer	0.000287	0.000586	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—ERBB2—brain cancer	0.000286	0.000585	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—ERBB2—brain cancer	0.000285	0.000582	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—EGFR—brain cancer	0.000285	0.000582	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—EGFR—brain cancer	0.000284	0.000579	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—STAT3—brain cancer	0.000283	0.000578	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	0.000283	0.000577	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PIK3CG—brain cancer	0.000281	0.000574	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—brain cancer	0.00028	0.000571	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—brain cancer	0.00028	0.000571	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	0.000279	0.00057	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—STAT3—brain cancer	0.000278	0.000568	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—brain cancer	0.000277	0.000565	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—ERBB2—brain cancer	0.000274	0.000559	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—brain cancer	0.000273	0.000558	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	0.000273	0.000558	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—PDGFRA—brain cancer	0.00027	0.000552	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—EGFR—brain cancer	0.000269	0.000548	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—brain cancer	0.000265	0.000542	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ABR—brain cancer	0.000262	0.000535	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—PDGFRA—brain cancer	0.000259	0.00053	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—CCND1—brain cancer	0.000258	0.000527	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—brain cancer	0.000257	0.000525	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	0.000257	0.000525	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—CTNNB1—brain cancer	0.000256	0.000522	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—STAT3—brain cancer	0.000255	0.00052	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GLI2—brain cancer	0.000253	0.000517	CbGpPWpGaD
Lithium—GSK3A—Immune System—SKP2—brain cancer	0.000252	0.000515	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PIK3CG—brain cancer	0.000251	0.000512	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—APC—brain cancer	0.00025	0.00051	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTCH2—brain cancer	0.000247	0.000504	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—brain cancer	0.000246	0.000503	CbGpPWpGaD
Lithium—GSK3A—Disease—SHH—brain cancer	0.000246	0.000501	CbGpPWpGaD
Lithium—GSK3A—Disease—ENO2—brain cancer	0.000246	0.000501	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—VAV1—brain cancer	0.000244	0.000498	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—EGFR—brain cancer	0.000242	0.000495	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES5—brain cancer	0.000239	0.000488	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GLI1—brain cancer	0.000238	0.000486	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HES1—brain cancer	0.000237	0.000485	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IRS2—brain cancer	0.000237	0.000484	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—STAT3—brain cancer	0.000236	0.000482	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—brain cancer	0.000235	0.00048	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—VAV1—brain cancer	0.000234	0.000478	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STRADA—brain cancer	0.000232	0.000474	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—brain cancer	0.000231	0.000472	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—STAT3—brain cancer	0.000231	0.000471	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—brain cancer	0.00023	0.00047	CbGpPWpGaD
Lithium—GSK3B—Disease—IDH1—brain cancer	0.00023	0.000469	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	0.000229	0.000468	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—CTNNB1—brain cancer	0.000229	0.000468	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—brain cancer	0.000229	0.000468	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—brain cancer	0.000228	0.000465	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—IRS2—brain cancer	0.000228	0.000465	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—RELA—brain cancer	0.000226	0.000462	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SUFU—brain cancer	0.000226	0.00046	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—VEGFA—brain cancer	0.000225	0.00046	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—brain cancer	0.000225	0.000459	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—CTNNB1—brain cancer	0.000222	0.000453	CbGpPWpGaD
Lithium—GSK3B—Disease—HEY1—brain cancer	0.000218	0.000444	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GFAP—brain cancer	0.000218	0.000444	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—STAT3—brain cancer	0.000218	0.000444	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	0.000214	0.000438	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—brain cancer	0.000214	0.000438	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—brain cancer	0.000214	0.000438	CbGpPWpGaD
Lithium—GSK3B—Disease—DLL1—brain cancer	0.000213	0.000436	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—brain cancer	0.000213	0.000434	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—RELA—brain cancer	0.000212	0.000433	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB2—brain cancer	0.000211	0.00043	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—brain cancer	0.000211	0.00043	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—EGFR—brain cancer	0.00021	0.000428	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	0.000209	0.000427	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HEY1—brain cancer	0.000206	0.000421	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—CTNNB1—brain cancer	0.000206	0.000421	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—brain cancer	0.000203	0.000414	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—DLL1—brain cancer	0.000202	0.000413	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PDGFRA—brain cancer	0.0002	0.000408	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—EGFR—brain cancer	0.000198	0.000405	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—brain cancer	0.000198	0.000404	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ABR—brain cancer	0.000194	0.000395	CbGpPWpGaD
Lithium—GSK3A—Immune System—VAV1—brain cancer	0.000192	0.000392	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PDGFRA—brain cancer	0.000192	0.000391	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ERBB2—brain cancer	0.000191	0.000389	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	0.00019	0.000388	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLI2—brain cancer	0.000187	0.000382	CbGpPWpGaD
Lithium—GSK3B—Immune System—SKP2—brain cancer	0.000186	0.00038	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CDK4—brain cancer	0.000186	0.00038	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—MYC—brain cancer	0.000186	0.000379	CbGpPWpGaD
Lithium—GSK3B—Disease—SHH—brain cancer	0.000181	0.000371	CbGpPWpGaD
Lithium—GSK3B—Disease—ENO2—brain cancer	0.000181	0.000371	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—MYC—brain cancer	0.00018	0.000367	CbGpPWpGaD
Lithium—GSK3A—Disease—VAV1—brain cancer	0.000177	0.000362	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLI1—brain cancer	0.000176	0.000359	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IRS2—brain cancer	0.000175	0.000358	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VEGFA—brain cancer	0.000173	0.000353	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SHH—brain cancer	0.000172	0.000351	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—STAT3—brain cancer	0.000171	0.00035	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—CTNNB1—brain cancer	0.00017	0.000347	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—IRS2—brain cancer	0.000168	0.000344	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—MYC—brain cancer	0.000167	0.000341	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SUFU—brain cancer	0.000167	0.00034	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TRPC6—brain cancer	0.000166	0.000339	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—RELA—brain cancer	0.000164	0.000334	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTCH1—brain cancer	0.000163	0.000333	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMO—brain cancer	0.000163	0.000333	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB2—brain cancer	0.000163	0.000332	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—brain cancer	0.000163	0.000332	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GFAP—brain cancer	0.000161	0.000328	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—STAT3—brain cancer	0.000161	0.000328	CbGpPWpGaD
Lithium—GSK3A—Immune System—PDGFRA—brain cancer	0.000157	0.000321	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—RELA—brain cancer	0.000157	0.000321	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB2—brain cancer	0.000156	0.000319	CbGpPWpGaD
Lithium—GSK3A—Disease—HES1—brain cancer	0.000153	0.000312	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HEY1—brain cancer	0.000152	0.000311	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—DLL1—brain cancer	0.000149	0.000305	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—brain cancer	0.000147	0.0003	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—brain cancer	0.000146	0.000298	CbGpPWpGaD
Lithium—GSK3A—Disease—PDGFRA—brain cancer	0.000145	0.000297	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CTNNB1—brain cancer	0.000142	0.000291	CbGpPWpGaD
Lithium—GSK3B—Immune System—VAV1—brain cancer	0.000142	0.00029	CbGpPWpGaD
Lithium—GSK3A—Immune System—IRS2—brain cancer	0.000138	0.000282	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—MYC—brain cancer	0.000138	0.000281	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RELA—brain cancer	0.000137	0.00028	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ERBB2—brain cancer	0.000136	0.000278	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—brain cancer	0.000132	0.00027	CbGpPWpGaD
Lithium—GSK3B—Disease—VAV1—brain cancer	0.000131	0.000268	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—brain cancer	0.000131	0.000267	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH2—brain cancer	0.00013	0.000266	CbGpPWpGaD
Lithium—GSK3A—Disease—IRS2—brain cancer	0.000128	0.00026	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SHH—brain cancer	0.000127	0.000259	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CTNNB1—brain cancer	0.000124	0.000254	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VAV1—brain cancer	0.000124	0.000254	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TRPC6—brain cancer	0.000123	0.00025	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RELA—brain cancer	0.000121	0.000247	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTCH1—brain cancer	0.00012	0.000246	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMO—brain cancer	0.00012	0.000246	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB2—brain cancer	0.00012	0.000245	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—CTNNB1—brain cancer	0.000119	0.000243	CbGpPWpGaD
Lithium—GSK3B—Immune System—PDGFRA—brain cancer	0.000116	0.000237	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RELA—brain cancer	0.000116	0.000237	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB2—brain cancer	0.000115	0.000236	CbGpPWpGaD
Lithium—GSK3B—Disease—HES1—brain cancer	0.000113	0.00023	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—brain cancer	0.000113	0.00023	CbGpPWpGaD
Lithium—GSK3A—Disease—APC—brain cancer	0.000113	0.00023	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—brain cancer	0.000108	0.000221	CbGpPWpGaD
Lithium—GSK3B—Disease—PDGFRA—brain cancer	0.000107	0.000219	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HES1—brain cancer	0.000107	0.000218	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CTNNB1—brain cancer	0.000105	0.000215	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—brain cancer	0.000105	0.000214	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—STAT3—brain cancer	0.000104	0.000212	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRS2—brain cancer	0.000102	0.000208	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDGFRA—brain cancer	0.000102	0.000208	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SPP1—brain cancer	9.88e-05	0.000202	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH2—brain cancer	9.63e-05	0.000197	CbGpPWpGaD
Lithium—GSK3A—Immune System—RELA—brain cancer	9.54e-05	0.000195	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB2—brain cancer	9.48e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—brain cancer	9.43e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Disease—IRS2—brain cancer	9.43e-05	0.000192	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VAV1—brain cancer	9.18e-05	0.000187	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IRS2—brain cancer	8.93e-05	0.000182	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB2—brain cancer	8.75e-05	0.000179	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL2—brain cancer	8.59e-05	0.000175	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—brain cancer	8.33e-05	0.00017	CbGpPWpGaD
Lithium—GSK3B—Disease—APC—brain cancer	8.33e-05	0.00017	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTNNB1—brain cancer	8.29e-05	0.000169	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—brain cancer	8e-05	0.000163	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HES1—brain cancer	7.9e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3CG—brain cancer	7.89e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APC—brain cancer	7.89e-05	0.000161	CbGpPWpGaD
Lithium—GSK3A—Disease—CTNNB1—brain cancer	7.65e-05	0.000156	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDGFRA—brain cancer	7.52e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SPP1—brain cancer	7.3e-05	0.000149	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—brain cancer	7.23e-05	0.000148	CbGpPWpGaD
Lithium—GSK3B—Immune System—RELA—brain cancer	7.05e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB2—brain cancer	7e-05	0.000143	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—brain cancer	6.67e-05	0.000136	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IRS2—brain cancer	6.6e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—brain cancer	6.57e-05	0.000134	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB2—brain cancer	6.46e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL2—brain cancer	6.35e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Disease—MYC—brain cancer	6.2e-05	0.000127	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RELA—brain cancer	6.16e-05	0.000126	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB2—brain cancer	6.13e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Immune System—CTNNB1—brain cancer	6.13e-05	0.000125	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—brain cancer	6.06e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APC—brain cancer	5.83e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3CG—brain cancer	5.83e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Disease—CTNNB1—brain cancer	5.66e-05	0.000115	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL2—brain cancer	5.55e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCND1—brain cancer	5.41e-05	0.000111	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CTNNB1—brain cancer	5.36e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—brain cancer	5.34e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—brain cancer	4.93e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—brain cancer	4.85e-05	9.91e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—brain cancer	4.72e-05	9.63e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—brain cancer	4.67e-05	9.54e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MYC—brain cancer	4.58e-05	9.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RELA—brain cancer	4.56e-05	9.3e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB2—brain cancer	4.53e-05	9.24e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—brain cancer	4.48e-05	9.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MYC—brain cancer	4.34e-05	8.86e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—brain cancer	4.25e-05	8.67e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL2—brain cancer	4.1e-05	8.38e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCND1—brain cancer	4e-05	8.17e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CTNNB1—brain cancer	3.96e-05	8.09e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—brain cancer	3.57e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—brain cancer	3.49e-05	7.12e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—brain cancer	3.45e-05	7.05e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MYC—brain cancer	3.21e-05	6.55e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—brain cancer	3.14e-05	6.41e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—brain cancer	2.63e-05	5.38e-05	CbGpPWpGaD
